Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 04-10 11:56:25 EDT

9.05

-0.24

-2.64%

High9.33	Low9.04	Vol156.52K
Open9.21	D1 Closing9.29	Amplitude3.12%
Mkt Cap283.02M	Tradable Cap141.94M	Total Shares31.29M
T/O1.44M	T/O Rate1.00%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":9.045,"timestamp":1775836573560,"preClose":9.29,"halted":0,"volume":156519,"delay":0,"changeRate":-0.026372443487621015,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Trading","change":-0.245,"latestTime":"04-10 11:56:25 EDT","open":9.21,"high":9.33,"low":9.04,"amount":1438415.557722,"amplitude":0.031216,"askPrice":9.06,"askSize":141,"bidPrice":9.03,"bidSize":476,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775851200000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":9.29,"preHourTrading":{"tag":"盘前","latestPrice":9.26,"preClose":9.29,"latestTime":"09:28 EDT","volume":484,"amount":4491.353988,"timestamp":1775827681074,"change":-0.03,"changeRate":-0.003229,"amplitude":0.004769},"postHourTrading":{"tag":"盘后","latestPrice":9.29,"preClose":9.29,"latestTime":"18:13 EDT","volume":2517,"amount":23395.74,"timestamp":1775772821514,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.777166,"impliedVol":0.8021,"impliedVolPercentile":0.348},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2626134971","title":"Lyra Therapeutics Streamlines Operations with Major Lease Terminations","url":"https://stock-news.laohu8.com/highlight/detail?id=2626134971","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626134971?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:17","pubTimestamp":1775827075,"startTime":"0","endTime":"0","summary":"An announcement from Lyra Therapeutics ( ($LYRA) ) is now available. On March 31, 2026, Lyra Therapeutics, Inc. agreed to terminate its lease for 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lyra-therapeutics-streamlines-operations-with-major-lease-terminations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lyra-therapeutics-streamlines-operations-with-major-lease-terminations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626176194","title":"Whitehawk Therapeutics presents analysis of MUC16 at SGO","url":"https://stock-news.laohu8.com/highlight/detail?id=2626176194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626176194?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:13","pubTimestamp":1775819622,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics (WHWK) presented three posters from a real-world analysis supporting the therapeutic potential of targeting mucin 16 with a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-analysis-of-muc16-at-sgo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-analysis-of-muc16-at-sgo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","WHWK","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626007195","title":"Allarity Therapeutics Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2626007195","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626007195?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:44","pubTimestamp":1775814240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALLR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 05:44 ET (09:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626016437","title":"Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2626016437","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626016437?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:55","pubTimestamp":1775796908,"startTime":"0","endTime":"0","summary":"Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi XDC to next generation ADC platforms.\nSee our latest analysis for WuXi XDC Cayman.\nInvestors appear to be weighing WuXi XDC’s new ADC partnership against a mixed share price pattern. The 30 day share price return of 3.64% contrasts with a 90 day share price return decline of 13.75% and a 1 year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4139","LU2488822045.USD","SG9999014674.SGD","02268","BK4231","ADC","BK4080","BK1141","DCF","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626654091","title":"PharmaEssentia to Buy Forus Therapeutics for C$50 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2626654091","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626654091?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:52","pubTimestamp":1775796769,"startTime":"0","endTime":"0","summary":"PharmaEssentia  board approved the acquisition of a 100% equity stake in Forus Therapeutics for C$50 million, according to a Thursday Taiwan Exchange filing.Shares gained over 2% in Friday's late morning trade.The company will fund the acquisition through internal resources or proceeds from its 2023 global depositary receipt issuance.The deal will strengthen and expand the company's product presence in the Canadian market, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626165961","title":"Arovella Therapeutics Seeks ASX Quotation for 1.6 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626165961","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626165961?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:37","pubTimestamp":1775795862,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics has applied to the ASX for quotation of 1,600,000 new...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arovella-therapeutics-seeks-asx-quotation-for-1-6-million-new-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arovella-therapeutics-seeks-asx-quotation-for-1-6-million-new-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626153713","title":"AN2 Therapeutics Files $300 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2626153713","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626153713?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:50","pubTimestamp":1775771416,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics  filed a shelf registration statement with US regulators on late Thursday for the potential sale of up to $300 million in securities, to be offered from time to time.The filing covers common stock, preferred stock, debt securities, warrants and units.The company said it will not receive any proceeds from the sale of common stock by selling securityholders.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","LENZ","BK4007","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626058153","title":"AN2 Therapeutics Launches New $80 Million ATM Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2626058153","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626058153?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:34","pubTimestamp":1775770470,"startTime":"0","endTime":"0","summary":"An announcement from AN2 Therapeutics, Inc. ( ($ANTX) ) is now available. On April 9, 2026, AN2 Therapeutics entered into an Open Market Sale Agree...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/an2-therapeutics-launches-new-80-million-atm-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/an2-therapeutics-launches-new-80-million-atm-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626153108","title":"AN2 Therapeutics files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2626153108","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626153108?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:25","pubTimestamp":1775769944,"startTime":"0","endTime":"0","summary":"17:22 EDT AN2 Therapeutics (ANTX) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/an2-therapeutics-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/an2-therapeutics-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","BK4139","BK4539","ANTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626158414","title":"Galera Therapeutics Announces Share Conversions and Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2626158414","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626158414?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:40","pubTimestamp":1775767259,"startTime":"0","endTime":"0","summary":"Galera Therapeutics ( ($GRTX) ) has provided an announcement. On April 7, 2026, Galera Therapeutics, Inc. converted 76,479.175 shares of its Series...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galera-therapeutics-announces-share-conversions-and-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galera-therapeutics-announces-share-conversions-and-warrant-exercise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626158399","title":"enGene Therapeutics Rebrands as Company Nears Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2626158399","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626158399?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:38","pubTimestamp":1775767095,"startTime":"0","endTime":"0","summary":"enGene Holdings ( ($ENGN) ) has provided an update. enGene Therapeutics Inc., a clinical-stage, non-viral genetic medicines company focused on high...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/engene-therapeutics-rebrands-as-company-nears-commercialization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/engene-therapeutics-rebrands-as-company-nears-commercialization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626313161","title":"Dianthus Therapeutics Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2626313161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626313161?lang=en_us&edition=fundamental","pubTime":"2026-04-10 00:45","pubTimestamp":1775753100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DNTH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2026 12:45 ET (16:45 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626133572","title":"Quince Therapeutics Announces 1-for-10 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2626133572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626133572?lang=en_us&edition=fundamental","pubTime":"2026-04-09 22:17","pubTimestamp":1775744272,"startTime":"0","endTime":"0","summary":"Quince Therapeutics ( ($QNCX) ) has shared an update. Quince Therapeutics, Inc. will implement a 1-for-10 reverse stock split of its common stock, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-announces-1-for-10-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quince-therapeutics-announces-1-for-10-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104838685","title":"C4 Therapeutics and Roche Expand Partnership with New $1 Billion-Plus Cancer Drug Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1104838685","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104838685?lang=en_us&edition=fundamental","pubTime":"2026-04-09 22:10","pubTimestamp":1775743826,"startTime":"0","endTime":"0","summary":"C4 Therapeutics, Inc. (CCCC.O) announced on Thursday, April 9th, that it has entered into a new collaboration agreement with Swiss pharmaceutical giant Roche (ROPC.S) to jointly develop novel cancer...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","CCCC","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626382571","title":"Oruka Therapeutics Price Target Maintained With a $125.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2626382571","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626382571?lang=en_us&edition=fundamental","pubTime":"2026-04-09 22:01","pubTimestamp":1775743260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORKA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2026 10:01 ET (14:01 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626187287","title":"Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC","url":"https://stock-news.laohu8.com/highlight/detail?id=2626187287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626187287?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:50","pubTimestamp":1775739000,"startTime":"0","endTime":"0","summary":"CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND timelin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270992/0/en/Akari-Therapeutics-Participates-in-Virtual-Investor-What-This-Means-Interview-Discussing-Strategic-Partnership-with-WuXi-XDC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626872521","title":"Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2626872521","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626872521?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:00","pubTimestamp":1775736000,"startTime":"0","endTime":"0","summary":"Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270872/0/en/Cloudbreak-Pharma-Announces-Launch-of-Cloudbreakpharma-com-to-Raise-Awareness-of-its-Pipeline-of-Novel-First-in-Class-Therapeutics-to-Treat-Serious-Underserved-Ophthalmic-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626181816","title":"Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2626181816","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626181816?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:37","pubTimestamp":1775734653,"startTime":"0","endTime":"0","summary":"Shield Therapeutics ( ($GB:STX) ) just unveiled an announcement. Shield Therapeutics reported its strongest year to date in 2025, driven by a 56% i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shield-therapeutics-hits-record-accrufer-sales-and-turns-cash-flow-positive-in-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shield-therapeutics-hits-record-accrufer-sales-and-turns-cash-flow-positive-in-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626918924","title":"Press Release: Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2626918924","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626918924?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:30","pubTimestamp":1775734200,"startTime":"0","endTime":"0","summary":"Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals , where he oversaw the company's full development portfolio, including clinical, preclinical, and CMC activities, and worked closely with executive leadership and Kiora's board of directors to define and execute development strategy.\"Eric is a highly accomplished development leader with a proven ability to translate scientific innovation into clinically and commercially viable programs,\" said Marc Hedrick, M.D., MBA, Plus Therapeutics President and Chief Executive Officer. \"His experience building and advancing therapeutic pipelines, combined with his strategic and operational expertise, will be instrumental as we accelerate the advancement of REYOBIQ and our broader CNS oncology portfolio.\". CNSide Diagnostics, LLC is a ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4007","LENZ","CNS","BK4232","BK4022","PSTV","BK4135","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626218629","title":"Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2626218629","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626218629?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., April  09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deli","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270784/0/en/Rani-Therapeutics-Appoints-Dr-Sara-Kenkare-Mitra-as-Strategic-Advisor-to-Advance-Platform-and-Clinical-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0393},{"period":"1month","weight":-0.2219},{"period":"3month","weight":-0.3753},{"period":"6month","weight":-0.7605},{"period":"1year","weight":-0.5451},{"period":"ytd","weight":-0.4194}],"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.6,"avgChangeRate":-0.014924},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}